Cingulate Inc(CING) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.62 | Insider Own | 16.53% | Shs Outstand | 13.9M | Perf Week | - |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 17.82% | Insider Trans | 4.22% | Shs Float | 12.1M | Perf Month | 4.84% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.43 | Inst Own | 12.88% | Short Float | 8.38% | Perf Quarter | 3.11% |
| Income | -0.03B | P/S | - | EPS this Y | 51.97% | Inst Trans | 4.64% | Short Ratio | 8.34 | Perf Half Y | -7.26% |
| Sales | 0.00B | P/B | 2.95 | EPS next 5Y | 35.89% | ROA | -123.76% | Short Interest | 1.02M | Perf YTD | 14.75% |
| Book/sh | 1.69 | P/C | 2.55 | EPS past 3/5Y | 77.21% 50.7% | ROE | -198.74% | 52W High | -58.12% ($11.89) | Perf Year | 37.95% |
| Cash/sh | 1.95 | P/FCF | - | Sales past 3/5Y | - | ROIC | -117.85% | 52W Low | 57.59% ($3.16) | Perf 3Y | -95.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.29% | Gross Margin | - | Volatility(W/M) | 6.79% 5.86% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.5 | EPS Q/Q | 59.19% | Profit Margin | - | RSI (14) | 51.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.5 | Sales Q/Q | - | SMA20 | 3.23% ($4.82) | Beta | -0.88 | Target Price | $21.5 |
| Payout | - | Debt/Eq | 0.27 | Earnings | 2026/8/13 | SMA50 | -0.91% ($5.03) | Rel Volume | 0.63 | Prev Close | $5.19 |
| Employees | 14 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 28% - | SMA200 | -8.47% ($5.44) | Avg Volume(3M) | 0.12M | Price | $4.98 |
| IPO | 2021/12/8 | Option/Short | Yes/Yes | Trades | 360 | Volume | 76,669 | Change | -4.05% |
A US clinical-stage biotech company developing an ADHD treatment designed to provide sustained efficacy with once-daily dosing through its proprietary "PTR™" formulation technology. By leveraging precision timed-release technology, the company is driving innovation in patient convenience and treatment effectiveness.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
CING has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.0% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -95.2%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #383 of 597 in the industry
Based on market cap of $72M.
FAQ
What kind of company is CING?
CING belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CING?
The market cap of CING is approximately $72M, ranking 4,664 within its sector.
What is the 52-week high and low for CING?
CING has recorded a 52-week high of $11.89 and a low of $3.16.
